Literature DB >> 32372351

Physicochemical characterization and cytotoxicity of articaine-2-hydroxypropyl-β-cyclodextrin inclusion complex.

Jonny Burga-Sánchez1, Luiz Eduardo Nunes Ferreira2, Maria Cristina Volpato3, Luis Fernando Cabeça4, Mario Braga5, Leonardo Fernandes Fraceto6, Eneida de Paula5, Francisco Carlos Groppo3.   

Abstract

Articaine (ATC) is one of the most widely used local anesthetics in dentistry. Despite its safety, local toxicity has been reported. This study aimed to develop an ATC-2- hydroxypropyl-β-cyclodextrin inclusion complex (ATC HPβCD) and to assess its toxicity in vitro. The inclusion complex was performed by solubilization, followed by a fluorimetric and job plot assay to determine the complex stoichiometry. Scanning electron microscopy, DOSY- 1 H-NMR, differential scanning calorimetry (DSC), and sustained release kinetics were used to confirm the inclusion complex formation. In vitro cytotoxicity was analyzed by MTT assay and immunofluorescence in HGF cells. Fluorimetric and job plot assay determined the inclusion complex stoichiometry (ATC:HPβCD = 1:1) and complex formation time (400 min), as indicated by a strong host/guest interaction (Ka = 117.8 M - 1), complexed fraction (f = 41.4%), and different ATC and ATC HPβCD melting points (172 °C e 235 °C, respectively). The mean of cell viability was 31.87% and 63.17% for 20-mM ATC and 20-mM ATC HPβCD, respectively. Moreover, remarkable cell toxicity was observed with free ATC by immunofluorescence. These results indicate the ATC HPβCD complex could be used to improve the safety of ATC. Further research are needed to establish the anesthetic safety and effectiveness in vivo .

Entities:  

Keywords:  Articaine; Cell viability; Human gingival fibroblast; Hydroxypropyl-β-cyclodextrin

Mesh:

Substances:

Year:  2020        PMID: 32372351     DOI: 10.1007/s00210-020-01879-1

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  1 in total

1.  Antinociceptive effects of bupivacaine and its sulfobutylether-β-cyclodextrin inclusion complex in orofacial pain.

Authors:  Juliana Souza de Freitas Domingues; Silmara Martins Dias Dos Santos; Julia das Neves Rodrigues Ferreira; Bianca Miguel Monti; Darciane Favero Baggio; Wagner Hummig; Erika Ivanna Araya; Eneida de Paula; Juliana Geremias Chichorro; Luiz Eduardo Nunes Ferreira
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-08-01       Impact factor: 3.195

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.